Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2CNS 2

Conditions

Melanoma 3Pancreatic Neoplasms 2Gliosarcoma 2Glioma 2Glioblastoma 2Breast Neoplasms 2Brain Neoplasms 2Recurrence 1Neoplasms 1Neoplasm Metastasis 1Medulloblastoma 1Lung Neoplasms 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1

Interventions

Temozolomide 29Bevacizumab 14Radiotherapy 12Trastuzumab 10Lomustine 9Capecitabine 8paclitaxel-Angiopep-2 conjugate 6Nivolumab 6pembrolizumab 5dabrafenib 5abemaciclib 5Radiation 5icotinib 4Surgical Procedures, Operative 4Paclitaxel 4Lapatinib 4Irinotecan 4Flucytosine 4Dianhydrogalactitol 4Corticotropin-Releasing Hormone 4Chlorotoxin 4Carboplatin 4vocimagene amiretrorepvec 3verubulin 3tucatinib 3osimertinib 3motexafin gadolinium 3XL647 3Spermine Synthase 3Radiosurgery 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Brain Neoplasms × 1-methyltryptophan × Clear all
NCT02052648 2024-03-27

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

Lumos Pharma

Phase 1/2 Completed
160 enrolled 21 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT02502708 2020-06-04

Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

Lumos Pharma

Phase 1 Completed
81 enrolled
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡